Bleakley Financial Group LLC Buys Shares of 20,318 DexCom, Inc. $DXCM

Bleakley Financial Group LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 20,318 shares of the medical device company’s stock, valued at approximately $1,774,000.

Several other institutional investors have also added to or reduced their stakes in DXCM. Brighton Jones LLC boosted its stake in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in DexCom by 4.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical device company’s stock valued at $1,449,000 after purchasing an additional 974 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the last quarter. Alpine Bank Wealth Management bought a new position in shares of DexCom during the 1st quarter valued at $40,000. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in shares of DexCom by 936.3% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 236,284 shares of the medical device company’s stock valued at $16,136,000 after buying an additional 213,483 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DexCom stock opened at $70.33 on Friday. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The stock’s fifty day moving average is $72.37 and its 200 day moving average is $77.78. The stock has a market cap of $27.58 billion, a P/E ratio of 48.84, a P/E/G ratio of 1.49 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the firm earned $0.43 EPS. DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Robert W. Baird lowered their price target on DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 26th. Barclays increased their price target on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a report on Friday. William Blair raised DexCom to a “strong-buy” rating in a report on Thursday, July 31st. Finally, Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.19.

Insider Buying and Selling

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock valued at $564,733 in the last 90 days. 0.32% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.